### Guideline Request

- Internal request and external submission: Review the data for ponatinib.

### Panel Discussion

Based on the data in the noted references, ponatinib was added as a treatment option in the following circumstances:

#### Chronic phase CML

- For patients with inadequate initial response to prior TKI therapy
  - \( BCR-ABL/ABL \) transcript levels > 10% (IS) or < partial cytogenetic response (PCyR) on bone marrow cytogenetics at 3 months
  - Less than complete cytogenetic response (CCyR) at 12 and 18 months

- Continuation of therapy for patients who have been switched to ponatinib as early as 3 months for inadequate initial response to prior TKI therapy in CCyR 12 months and 18 months or PCyR at 12 months

- Loss of response (increase in \( BCR-ABL \) transcript levels or cytogenetic relapse) at 6, 12 and 18 months

- Disease progression to accelerated or blast phase CML on prior TKI therapy.

- Follow-up therapy for relapse following allogeneic HSCT

- Preferred treatment option for patients with T315I mutation

### References


### Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>